Gil G Mor MD, PhD, MSc
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Division Director, Reproductive Sciences; Director Reproductive Immunology Unit and Discovery to Cure Program; Editor in Chief, AJRI
Departments & OrganizationsDevelopmental Therapeutics
Obstetrics, Gynecology & Reproductive Sciences: Cancer Biology Group | Reproductive Immunology Group | Women's Reproductive Health Research Career Development Center
Gil Mor, M.D., Ph.D. is Professor of Obstetrics and Gynecology and Reproductive Science at Yale University School of Medicine. Dr. Mor has focused his studies on the interaction between reproductive organs and the innate immune system. In his research he examines topics related to the immunology of implantation, the role of apoptosis in tissue remodeling and cancer, as well as the role of inflammation in cancer formation and progression. Dr. Mor earned his Ph.D. in Immunoendocrinology from the Weizmann Institute of Science and his M.S. and M.D. from Hebrew University in Jerusalem.
He completed postgraduate training at the National Institutes of Health where he worked in the Laboratory of Immunology as a Postdoctoral Fellow. At Yale University, he serves as Director of the Reproductive Immunology Unit and the Translational Research Program, “Discovery To Cure” (DTC). The Reproductive Immunology Unit has made important contributions in our understanding of the immunology of the female reproductive tract in normal and abnormal conditions. His studies on apoptosis and cancer, primarily the role of the Fas/FasL system in tissue renewal and the regulation of apoptosis in cancer cells and immune cells, have been published in prestigious journals and are highly cited.
Further, Dr. Mor’s studies on the regulatory pathways controlling cell survival and apoptosis in ovarian cancer cells led to the characterization of a new compound, phenoxodiol, which was used as a chemosensitizer based on its capacity to reactivate the apoptotic cascade. In 2005, Dr. Mor’s laboratory developed and characterized a new test for the early detection of ovarian cancer. The test evaluated likelihood of developing ovarian cancer among high risk populations. This test has been licensed to several companies in the USA, China, Europe and Israel.
More recently, Dr. Mor’s laboratory identified a unique population of ovarian cancer cells with characteristics of stem cells. These findings have opened a new area of research which may help to understand the source of recurrence and chemoresistance. Dr. Mor has more than 170 publications and is the editor of two books on “Immunology of pregnancy” and “Apoptosis and Cancer”.Dr. Mor is recipient of several national and international prizes, including the J. Christian Herr Award-from the Society for Reproductive Immunology.
He is member of the American Association for Cancer Research and the Society for Gynecologic Investigation and the formerTreasurer of the American Society of Reproductive Immunology. He is also honorary member of several scientific societies in South America. Dr. Mor was elected as the Editor in Chief of the Journal of the American Society for Reproductive Immunology and is the member of the Editorial Board of numerous journals. Dr. Mor has five patents licensed to pharmaceutical companies. Dr. Mor is also founder and organizer of the DTC High School internship program; an educational program to promote science in high school students, undergraduate students, and science educators. The program is an internationally recognized educational activity, enrolling 30 students out of more than 200 applications per year. The program is supported by NIH/NCI and private foundations.